Stock Market & Financial Investment News

News Breaks January 18, 2013 07:07 EDT GSK, AZN Flu outbreak to lead to more powerful vaccines, Bloomberg reports With the worst flu outbreak since 2009 gripping the U.S., vaccine makers (GSK, AZN) are determined to do better next season. They’re developing powerful vaccines that hold the promise of cutting incidences of flu by the thousands, reports Bloomberg. Reference Link News For GSK;AZN From The Last 14 Days Check below for free stories on GSK;AZN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 10:36 EDT AZN Leerink's major/specialty pharma analyst holds analyst/Industry conference call Subscribe for More Information 08:41 EDT AZN Impax commenced shipment of authorized generic Zomig Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. May 14, 2013 07:24 EDT GSK, AZN EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:53 EDT AZN Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link 16:25 EDT GSK On The Fly: Closing Wrap Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. 15:55 EDT AZN Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says Subscribe for More Information 12:20 EDT GSK On The Fly: Midday Wrap Subscribe for More Information 05:44 EDT GSK Elan provides additional information on Elan/Theravance agreement Subscribe for More Information 05:35 EDT GSK Theravance, Elan enter into $1B royalty participation agreement Subscribe for More Information May 10, 2013 12:42 EDT GSK GlaxoSmithKline, Theravance confirm FDA approval of Breo Ellipta Subscribe for More Information 11:48 EDT AZN, GSK Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 11:15 EDT GSK FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease Subscribe for More Information 06:53 EDT GSK GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information May 9, 2013 10:17 EDT AZN Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 6, 2013 16:23 EDT AZN Array to start first company-led Phase 3 trial with MEK162 Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with Velcade® (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. 13:16 EDT AZN AstraZeneca management to meet with Jefferies Meeting to be held in New York on May 9 hosted by Jefferies. 07:49 EDT GSK Bernstein's global pharmaceuticals analyst has analyst/industry conference call Subscribe for More Information 07:27 EDT AZN Bristol-Myers, AstraZeneca announces results of metreleptin study Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.